Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The Company develops Jakafi (ruxolitinib), a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera when there has been an inadequate response to or intolerance of hydroxyurea.

Type
Public
HQ
Wilmington, US
Founded
1991
Size (employees)
1,208 (est)+24%
Website
incyte.com
Incyte was founded in 1991 and is headquartered in Wilmington, US
Report incorrect company information

Incyte Office Locations

Incyte has offices in Boulogne-Billancourt, Surrey, Planegg, Geneva and in 6 other locations
Wilmington, US (HQ)
1801 Augustine Rd
Wien, AT
DC Tower 1 7 Donau-City-Straße
Boulogne-Billancourt, FR
35 ter avenue André Morizet
Planegg, DE
9 Fraunhoferstraße
Milan, IT
Via Fabio Filzi 25/A
Amsterdam, NL
Paasheuvelweg 25
Show all (10)
Report incorrect company information

Incyte Financials and Metrics

Incyte Revenue

Incyte's revenue was reported to be $1.54 b in FY, 2017
USD

Revenue (Q1, 2018)

382.3 m

Net income (Q1, 2018)

(41.1 m)

EBIT (Q1, 2018)

(67.1 m)

Market capitalization (18-Jul-2018)

14.9 b

Closing share price (18-Jul-2018)

70.4

Cash (31-Mar-2018)

894.4 m
Incyte's current market capitalization is $14.9 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

354.9 m511.5 m753.8 m1.1 b1.5 b

Revenue growth, %

44%47%47%

General and administrative expense

303.3 m366.4 m

R&D expense

581.9 m1.3 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

85.1 m89.8 m99.6 m198.1 m159.3 m163 m187.6 m263.5 m246.3 m269.5 m384.1 m326.4 m382.3 m

General and administrative expense

26.4 m37 m40.9 m39.4 m44.9 m51.7 m47.6 m64.6 m66.8 m75.8 m87.2 m90.1 m121.5 m

R&D expense

71.7 m75.6 m84.7 m88.5 m118.4 m112.4 m132.1 m156.8 m120.3 m143.2 m408 m201.8 m303.1 m

Operating expense total

98.3 m112.7 m125.8 m128.2 m166.2 m170.4 m187.7 m227.4 m201.7 m247.2 m517.4 m319.2 m449.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

471.4 m452.3 m521.4 m652.3 m899.5 m

Accounts Receivable

35.4 m57.9 m114.5 m148.8 m266.3 m

Inventories

9.6 m20.5 m17.8 m4.1 m6.5 m

Current Assets

555.8 m699.2 m842.4 m994.2 m1.5 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

272.1 m436.6 m406.3 m382 m421.8 m439.7 m445.8 m657.6 m487.7 m580.1 m361.8 m451.8 m894.4 m

Accounts Receivable

33.2 m46.4 m47.2 m109.6 m69.6 m75.1 m87 m101.3 m129.5 m131.5 m245 m169.5 m220.2 m

Inventories

359 k347 k269 k402 k2.4 m1.9 m2.4 m1.3 m6.1 m4.1 m4 m2.9 m4.6 m

Current Assets

333.7 m581.2 m577.1 m662.6 m692.1 m733 m757.9 m935.6 m792.1 m886.7 m819.2 m844.8 m1.5 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(83.1 m)(48.5 m)6.5 m104.2 m(313.1 m)

Depreciation and Amortization

58.4 m52.2 m

Inventories

(6.6 m)(4.1 m)17.8 m4 m4.9 m

Accounts Payable

5.1 m5.4 m30.1 m43.8 m(7.9 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(22 m)(34 m)(36.9 m)59.3 m(18.4 m)(39.6 m)24 m34.4 m36.9 m(187.1 m)(41.1 m)

Depreciation and Amortization

13.4 m

Inventories

269 k402 k2.4 m1.9 m2.4 m1.3 m6.1 m4.1 m4 m1.9 m

Accounts Payable

27.3 m26.6 m26.6 m29.2 m27.4 m31.9 m40.7 m57.5 m86.3 m6.4 m
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Incyte Online and Social Media Presence

Embed Graph
Report incorrect company information

Incyte News and Updates

Saddled with a black box and low dose, Lilly, Incyte RA drug Olumiant faces uphill fight

The 2 mg dose of Eli Lilly and Incyte's rheumatoid arthritis drug Olumiant picked up an FDA approval after independent experts flagged safety concerns on the 4 mg dose. And with a black-box warning on its label, the new med will face an uphill fight for sales.

Serine/Threonine Protein Kinase Pim 3 Pipeline Review| Companies Involved in Therapeutics Development: Incyte Corp, Jasco Pharmaceuticals, Novartis AG

Serine/Threonine Protein Kinase Pim 3 Pipeline Review| Latest Developments by Type, by End-Users/Application, by Region - Forecast and Business Outlook Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more
Report incorrect company information

Incyte Company Life and Culture

Report incorrect company information